UPPSALA, SWEDEN – December 17, 2014. Oasmia Pharmaceutical AB (publ) announced today that from January 2, 2015, the company will be listed at the Mid Cap segment of Nasdaq Stockholm.
The move is made possible after Nasdaq’s annual review of its Nordic market capitalization (market cap) segments. The Mid Cap list includes companies with a market cap between EUR 150 million and EUR 1 billion.
“We are very pleased with the move, since this means that we are now able to attract potential investors that are not permitted to invest in companies in the Small Cap segment”, commented Julian Aleksov, President and CEO of Oasmia.
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ OMX Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365).